What changed from existing technology?
This study looks at how estrogen receptors affect the immune system in breast cancer, showing that they can both suppress and boost the immune response, which could change how we treat the disease.
The review highlights the emerging role of estrogen receptors in modulating the tumor immune microenvironment, which is a new perspective compared to their traditionally understood tumor-intrinsic effects.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
erapy, especially in high-risk breast cancers. Ongoing clinical trials are investigating how altered ER signaling influences responses in both early and metastatic
Abstract ↗x interactions with the tumor immune microenvironment remain less understood. Recent clinical studies highlight the predictive value of ERα and suggest t
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings suggest that ERα status could be a predictive biomarker for immunotherapy response in high-risk breast cancers, potentially guiding treatment strategies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.